Health Care [ 6/12 ] | Biotechnology [ 27/74 ]
NASDAQ | Common Stock
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases.
The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma.
It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types.
In addition, the company's products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV).
Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis.
Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 25 | -0.37 Increased by +98.85% | -0.16 Decreased by -133.00% |
| Nov 5, 24 | 0.17 Decreased by -95.75% | -0.35 Increased by +148.57% |
| Aug 8, 24 | -0.23 Increased by +37.84% | -0.48 Increased by +52.08% |
| May 8, 24 | -0.49 Increased by +98.60% | -0.36 Decreased by -36.11% |
| Feb 28, 24 | -32.22 Increased by +40.33% | -21.74 Decreased by -48.21% |
| Nov 7, 23 | 4.00 Decreased by -66.67% | -28.92 Increased by +113.83% |
| Aug 10, 23 | -0.37 Increased by +97.36% | -32.10 Increased by +98.85% |
| May 10, 23 | -35.00 Increased by +5.41% | -32.19 Decreased by -8.73% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 84.05 M Decreased by -20.43% | -23.77 M Increased by +10.02% | Decreased by -28.28% Decreased by -13.09% |
| Sep 30, 24 | 80.25 M Increased by +28.14% | 8.74 M Increased by +277.23% | Increased by +10.89% Increased by +194.39% |
| Jun 30, 24 | 75.40 M Increased by +57.86% | -11.62 M Increased by +17.48% | Decreased by -15.41% Increased by +47.73% |
| Mar 31, 24 | 70.50 M Increased by +58.29% | -24.44 M Decreased by -46.35% | Decreased by -34.66% Increased by +7.54% |
| Dec 31, 23 | 105.64 M Increased by +119.79% | -26.42 M Decreased by -4.82% | Decreased by -25.01% Increased by +52.31% |
| Sep 30, 23 | 62.62 M Increased by +52.01% | 2.32 M Decreased by -62.82% | Increased by +3.70% Decreased by -75.54% |
| Jun 30, 23 | 47.76 M Increased by +49.25% | -14.08 M Decreased by -129.98% | Decreased by -29.47% Decreased by -54.09% |
| Mar 31, 23 | 44.54 M Increased by +98.19% | -16.70 M Decreased by -3.53% | Decreased by -37.49% Increased by +47.76% |